ALS Association invests $3M to bring access to care closer to home

A cellular recycling system that degrades damaged or unwanted proteins is impaired in motor neurons from people with amyotrophic lateral sclerosis (ALS), suggesting it could be a target for future therapies aimed at slowing disease progression, according to a new study. The research also showed that motor neurons in…

EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with amyotrophic lateral sclerosis (ALS) to clinical trials. The platform is available for free through the EverythingALS website or as a mobile app, providing patients with a secure way…

Getting out of the house is always a challenge because my husband, Todd, has ALS and needs care almost 24/7. I never know if I’ll make it to my Monday night ukulele group. When I do, I’m usually rushing to feed Todd, help him in the bathroom, and get…

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to tazbentetol, an experimental oral therapy being developed by Spinogenix for amyotrophic lateral sclerosis (ALS). Fast-track status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. It will allow Spinogenix…

As soon as I reached for the sock, I knew it would fall to the floor. And it did. I retrieved it by slowly bending sideways in my chair, stretching my arm in its direction, and with a mighty oomph, finally seized the soft fabric. That was just one speed…

Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its lead clinical candidate for amyotrophic lateral sclerosis (ALS) and related diseases, toward clinical trials. The grant was supported by cell-based studies showing that AS-241 can restore certain ALS-related defects…

Following a recent meeting with the U.S. Food and Drug Administration (FDA), Clene is planning to submit an application asking the agency to approve its experimental therapy CNM-Au8 as a treatment for amyotrophic lateral sclerosis (ALS). The company specifically plans to file a new drug application (NDA)…

People with amyotrophic lateral sclerosis (ALS) who received a high dose of the experimental therapy dazucorilant had a significantly higher chance of survival than patients given a lower dose or no treatment. That’s according to new analyses of data from the DAZALS Phase 2 clinical trial (NCT05407324), which…

May is ALS Awareness Month, and in the U.S. and around the world, organizations are educating, sponsoring events, and encouraging the community to join them in taking action, providing financial support, and pushing for better access to care through advocacy for those living with amyotrophic lateral sclerosis. The…